Q3 EPS Estimate for OnKure Therapeutics Increased by Analyst

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for OnKure Therapeutics in a report issued on Tuesday, August 26th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.17) per share for the quarter, up from their previous forecast of ($1.28). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.56) EPS, Q1 2026 earnings at ($1.01) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.19) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.09.

Several other research firms have also weighed in on OKUR. Evercore ISI began coverage on shares of OnKure Therapeutics in a research note on Wednesday, April 30th. They set an “outperform” rating for the company. Zacks Research lowered shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, OnKure Therapeutics currently has an average rating of “Buy” and a consensus target price of $32.33.

OnKure Therapeutics Trading Up 1.8%

OKUR stock opened at $2.80 on Thursday. The stock’s 50 day simple moving average is $2.42 and its 200 day simple moving average is $3.17. OnKure Therapeutics has a 12-month low of $1.70 and a 12-month high of $20.00. The firm has a market cap of $37.88 million, a P/E ratio of -0.58 and a beta of 0.40.

Institutional Trading of OnKure Therapeutics

Hedge funds have recently bought and sold shares of the company. Acorn Capital Advisors LLC acquired a new position in OnKure Therapeutics during the 4th quarter valued at about $12,381,000. Citadel Advisors LLC acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth approximately $8,782,000. Samsara BioCapital LLC acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth approximately $7,088,000. Vestal Point Capital LP bought a new position in OnKure Therapeutics in the 4th quarter worth approximately $5,461,000. Finally, Shay Capital LLC increased its position in OnKure Therapeutics by 417.8% in the 2nd quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock valued at $1,869,000 after acquiring an additional 631,008 shares during the period. 90.98% of the stock is currently owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.